Ingredients in every ml
|Ranitidine HCl||25 mg|
Each package contains
|ATC Level 1||A – Alimentary tract and metabolism|
|ATC Level 2||A02 – Drugs for Acid Related Disorders|
|ATC Level 3||A02B – Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)|
18 YEARS OLD AND ABOVE
Intramuscular (IM) injection:
50 mg (no dilution necessary) every 6-8 hours.
Intravenous (IV) injection: intermittent.
- Intermittent bolus: 50 mg (2 ml) every 6-8 hours.
Dilute ranitidine injection 50 mg in 0.9% sodium chloride solution or other compatible IV solution to a concentration not greater than 2.5 mg/ml (total volume of 20 ml). Rate of injection should not exceed 4 ml/minutes (for 5 minutes).
- Intermittent infusion: 50 mg (2 ml) every 6-8 hours.
Dilute ranitidine injection 50 mg in 100 mL of 5% dextrose solution or other compatible IV solution to a concentration not greater than 0.5 mg/ml (total volume of 100 ml). Rate of infusion should not exceed 5-7 ml/minutes (for 15-20 minutes).
- Continuous IV infusion:
Dilute ranitidine 150 mg in 250 ml of 5% dextrose solution or other compatible IV solution and rate of infusion is 6.25 mg/hour for 24 hours.
For Zollinger-Ellison syndrome or other pathological hypersecretory conditions, ranitidine injection should be diluted to a concentration not greater than 2.5 mg/ml with 5% dextrose solution or other compatible IV solution. Initial infusion rate is 1 mg/kg body weight/hour and should be adjusted to patient's condition.
0 TO 18 YEARS OLD
Safety and efficacy in pediatrics has not been established
Active duodenal ulcer, pathological gastric ulcer, reflux esophagitis. Prevention of peptic ulcer relapse. Zollinger-Ellison syndrome.